Immuron Limited Sponsored ADR
(NASDAQ : IMRN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.38%197.271.2%$491.39m
GILDGilead Sciences, Inc.
-0.59%71.910.9%$443.58m
BIIBBiogen Inc.
0.39%316.761.3%$346.04m
ILMNIllumina, Inc.
-2.00%310.883.5%$334.54m
CELGCelgene Corporation
-0.79%79.971.2%$321.24m
VRTXVertex Pharmaceuticals Incorporated
-1.89%174.051.9%$231.80m
REGNRegeneron Pharmaceuticals, Inc.
-1.49%382.042.6%$220.65m
ALXNAlexion Pharmaceuticals, Inc.
-0.84%122.882.0%$216.29m
SRPTSarepta Therapeutics, Inc.
0.50%133.2216.4%$166.80m
AAgilent Technologies, Inc.
-2.89%62.421.5%$150.44m
BMRNBioMarin Pharmaceutical Inc.
-2.68%100.764.4%$135.65m
LGNDLigand Pharmaceuticals Incorporated
-1.69%181.7723.3%$116.21m
EXASExact Sciences Corporation
1.03%62.8925.3%$106.67m
ECYTEndocyte, Inc.
0.19%23.572.1%$96.06m
NBIXNeurocrine Biosciences, Inc.
-1.61%107.415.1%$94.15m

Company Profile

Immuron Ltd. engages in the research and development of oral immunotherapy treatments using dairy-derived antibody products for humans. It operates through the following segments: Research and Development; HyperImmune Products; and Corporate. The Research and Development segment involves the research and development projects performed in Australia and Israel. The HyperImmune Products segment comprises of Travelan activities which occur in Australia, New Zealand, Canada, and the United States. The Corporate segment covers corporate activities. The company was founded on January 13, 1994 and is headquartered in Southbank, Australia.